Novartis Loses Bids to Block Rival’s Entresto Copies Amid Suits

Novartis AG won a brief stay despite failing to block MSN Laboratories Private Ltd.’s generic version of Entresto while patent-infringement suits over the blockbuster heart-failure drug continue in Delaware district court and an appeals court.

Judge Richard G. Andrews issued two rulings Monday in the US District Court for the District of Delaware, both favorable for MSN’s Entresto copy, which the US Food and Drug Administration approved July 24. His first order denied Novartis’ motion for a preliminary injunction in its October 2022 suit alleging infringement of US Patent No. 11,096,918. The second order rejected Novartis’ request for an ...